These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16508734)

  • 1. Timing of significant adverse events is essential information during early development of new drugs.
    Hyodo I
    Int J Clin Oncol; 2006 Feb; 11(1):69; author reply 69-70. PubMed ID: 16508734
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of capecitabine in cancer: management of the hand foot syndrome.
    Sudoyo AW
    Acta Med Indones; 2005; 37(3):174-6. PubMed ID: 16110178
    [No Abstract]   [Full Text] [Related]  

  • 3. A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumors.
    Saeki T; Takashima S; Terashima M; Satoh A; Toi M; Osaki A; Toge T; Ohno S; Nomura N; Fukuyama Y; Koizumi W; Taguchi T
    Int J Clin Oncol; 2005 Feb; 10(1):51-7. PubMed ID: 15729602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of xeloda (capecitabine) in the treatment of cancer patients (review)].
    Orel NF
    Ter Arkh; 2003; 75(10):65-70. PubMed ID: 14669610
    [No Abstract]   [Full Text] [Related]  

  • 5. Capecitabine: have we got the dose right?
    Midgley R; Kerr DJ
    Nat Clin Pract Oncol; 2009 Jan; 6(1):17-24. PubMed ID: 18936793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
    Ratain MJ
    J Clin Oncol; 2002 Mar; 20(6):1434-5. PubMed ID: 11896086
    [No Abstract]   [Full Text] [Related]  

  • 7. Capecitabine-induced oromandibular dystonia: a case report and literature review.
    Ngeow JY; Prakash KM; Chowbay B; Quek ST; Choo SP
    Acta Oncol; 2008; 47(6):1161-5. PubMed ID: 18607849
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
    Gallerani E; Bauer J; Hess D; Boehm S; Droege C; Jeckelmann S; Miani M; Herrmann R; Marsoni S; Sperka S; Sessa C
    Acta Oncol; 2011 Oct; 50(7):1105-10. PubMed ID: 21184645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
    Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
    Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
    Seminara P; Losanno T; Emiliani A; Manna G
    Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acute coronary syndrome during oral capecitabine monotherapy].
    Martí V; Monell J; Seixo F; Falces C
    Rev Esp Cardiol; 2008 May; 61(5):548-9. PubMed ID: 18462663
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of capecitabine use in patients with liver dysfunction.
    Saif MW; Tejani MA
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):730-2; discussion 736. PubMed ID: 17982413
    [No Abstract]   [Full Text] [Related]  

  • 13. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
    Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
    J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
    Mignogna MD; Fortuna G; Falleti J; Leuci S
    Eur J Clin Pharmacol; 2009 Oct; 65(10):1057-9. PubMed ID: 19521695
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
    Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
    J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine-induced pancreatitis.
    Jones KL; Valero V
    Pharmacotherapy; 2003 Aug; 23(8):1076-8. PubMed ID: 12921254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis.
    Jhaveri KD; Flombaum C; Shah M; Latcha S
    J Oncol Pharm Pract; 2012 Mar; 18(1):140-7. PubMed ID: 22392964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation of actinic keratoses with capecitabine therapy for colon cancer.
    Serrão VV; Feio AB
    Eur J Dermatol; 2008; 18(2):200. PubMed ID: 18424393
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Dunst J; Reese T; Sutter T; Zühlke H; Hinke A; Kölling-Schlebusch K; Frings S
    J Clin Oncol; 2002 Oct; 20(19):3983-91. PubMed ID: 12351595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of capecitabine: a review.
    Mikhail SE; Sun JF; Marshall JL
    Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.